INDV vs. ELAN, RVMD, LEGN, GRFS, TGTX, NUVL, LNTH, TLX, AXSM, and AKRO
Should you be buying Indivior stock or one of its competitors? The main competitors of Indivior include Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry.
Indivior vs. Its Competitors
Elanco Animal Health (NYSE:ELAN) and Indivior (NASDAQ:INDV) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.
Elanco Animal Health has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.
Elanco Animal Health currently has a consensus price target of $15.33, suggesting a potential upside of 3.95%. Indivior has a consensus price target of $17.00, suggesting a potential upside of 12.06%. Given Indivior's stronger consensus rating and higher probable upside, analysts clearly believe Indivior is more favorable than Elanco Animal Health.
In the previous week, Elanco Animal Health had 4 more articles in the media than Indivior. MarketBeat recorded 10 mentions for Elanco Animal Health and 6 mentions for Indivior. Indivior's average media sentiment score of 0.50 beat Elanco Animal Health's score of 0.43 indicating that Indivior is being referred to more favorably in the news media.
Elanco Animal Health has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.
Elanco Animal Health has a net margin of 8.43% compared to Indivior's net margin of -4.02%. Elanco Animal Health's return on equity of 7.54% beat Indivior's return on equity.
97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 0.9% of Elanco Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Elanco Animal Health beats Indivior on 11 of the 16 factors compared between the two stocks.
Get Indivior News Delivered to You Automatically
Sign up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding INDV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Indivior Competitors List
Related Companies and Tools
This page (NASDAQ:INDV) was last updated on 7/9/2025 by MarketBeat.com Staff
